Neurogene Q2 net loss widens to $34.5 million; cash runway extends into 2029
Neurogene reported second quarter 2026 results, with a net loss of $34.5 million versus $22.0 million a year earlier, driven by higher R&D and G&A expenses including a one-time stock-based compensation catch-up charge. The company also said an oversubscribed public offering of about $144 million gross proceeds extends its cash runway into the first quarter of 2029, and it reported updated Phase 1/2 data for NGN-401 in Rett syndrome.
Key points
- Net loss was $34.5 million for the quarter ended June 30, 2026, compared with $22.0 million a year earlier.
- R&D expenses rose to $25.5 million from $19.4 million; G&A expenses rose to $11.2 million from $6.7 million.
- Pro forma cash, cash equivalents and short-term investments were about $360.2 million, including about $134.8 million of net proceeds from the July 2, 2026 offering.
- Topline Embolden registrational data are expected in the second half of 2027.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.